GLP-1s have taken the U.S. healthcare system by storm as more Americans look to GLP-1s for the treatment of diabetes and obesity.
Omada recognizes that the sudden increase in the use of GLP-1s for weight loss presents unique concerns surrounding costs and long-term efficacy. As always, we continue to follow the science surrounding weight loss management and listen to industry developments.
In this white paper you will find the answers to frequently asked questions from benefit plan managers and payers as they navigate the use of GLP-1s for weight loss.
Want to learn more about Omada’s innovation in this space? Contact Omada today.